The FDA on May 28, 2021 granted accelerated approval to LUMAKRAS®, a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. LUMAKRAS® is a product of Amgen, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
